Stock Analysis·← Pickers

RZLT

Rezolute, Inc.

Rezolute, Inc. (RZLT) is currently in a range/mixed trend, above the 50-day MA but below the 200-day MA. RSI is at 48.3, with 1/3 trend checks passing.

Price
$4.58
-0.15 (-3.27%)
Day range
$4.51–$4.72
52wk $1.07–$11.46
Volume
119.1K
Avg
Trend score
1/3
Range / Mixed
RSI (14)
48.3
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

RZLT with MA50 and MA200

10.948.556.173.791.4008/0110/2701/2304/2007/16
RZLT2025-08-012026-07-16
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$4.14+10.83% vs price
MA200
$4.94-7.12% vs price
RSI (14)
48.3Neutral zone
MACD Signal
BearishMomentum below signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Valuation

RZLT valuation multiples (TTM)

P/E Ratio
P/S Ratio
P/B Ratio
EV/EBITDA
Valuation multiples are provided by Financial Modeling Prep when available.
Analyst Ratings

RZLT analyst consensus

Avg Price Target
High Target
Low Target
Analyst Coverage
Analyst ratings and price targets are provided by Financial Modeling Prep when available.
Chart Summary
Trend summary for RZLT

Rezolute, Inc. (RZLT) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $4.58, and 1 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 10.8% and below the 200-day moving average by 7.1%.

Momentum and stretch context

RZLT currently has an RSI reading of 48.3, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.

What traders may watch next

This page is designed to help you quickly understand what the RZLT chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.

Company profile

About Rezolute, Inc.

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Nevan Charles Elam
Employees
71
Market cap
$436.7M
Beta
0.55
52-week range
$1.07 – $11.46
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
14 Jan 2013
ISIN
US76200L3096
CUSIP
76200L309
Company profile data from Financial Modeling Prep. RZLT listed on NASDAQ.
Share dilution

RZLT shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Jun 2019Mar 2026
Shares outstanding (latest)
104.0M
Since Jun 2019
+1823.5%
Trend
More shares outstanding
Historical shares-outstanding data from Financial Modeling Prep. RZLT28 data points from Jun 2019 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about RZLT

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.